We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MSD has lifted the curtain on strong Phase 3 results in the development of its investigational antiviral drug letermovir, showing the treatment hit its primary endpoint of an improvement in clinically significant cytomegalovirus (CMV) infection following